$イオン バイオファーマ インク A(AEON.US)$coming off the watchlist. Company has never turned a profit since it started (common enough for pharmaceutical R&D company like this), quarterly report seems to confirm their flagship product development is ineffective. Company will need to do some serious cap raising to stay afloat. Leave this one and take your money elsewhere.
$イオン バイオファーマ インク A(AEON.US)$on the watchlist, phase 2 trial seemed okay other than unexpectedly strong result from placebo, interested to see how phase 3 goes. Might look to enter if price goes lower.
$イオン バイオファーマ インク A(AEON.US)$ this is depressing. wonder will the counter just get itself delisted from the market? people just treat the compat withour any single hope?
Johnny Mnemonicスレ主BSDLucky:
it's severely oversold, buyers are showing a willingness to enter, 5 leg down has already been completed pre bad news(sell off), free float is below 20m, but I would like to see the turnover around 50% of the volume
BSDLuckyJohnny Mnemonicスレ主:
Fundamentally it seems nothing else the company can offer at this point. It’s a “nothing” at this point as the hopeful candidate to pass the phase 2 failed “miserably” at this junctions. So, what make the team/researcher/company think ppl should invest in the company moving forward? It’s not like they have any ready product at one hand and R&D new products on the other hand.
$イオン バイオファーマ インク A(AEON.US)$ NEWS AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine AEON Biopharma announced that the preliminary results from the Phase 2 trial with ABP-450 for chronic migraine prevention did not meet the primary endpoint of mean reduction in monthly migraine days. The trial showed no statistical significance in reduction compared to placebo, leading to the company initiating cash preserva...
3
1
報告
Stock_Drift :
And you can buy it for a song right now, too.
$イオン バイオファーマ インク A(AEON.US)$Press Release: AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements Dow Jones· 5 mins ago
$イオン バイオファーマ インク A(AEON.US)$AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine 1 MINUTE AGO, 4:30 PM EDT VIA GLOBENEWSWIRE – FDA and AEON align on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine – – An interim analysis from the ongoing Phase 2 study in chronic migraine will now be conducted and data are e...
10
報告
Jaguar8 :
I so love this! I got tired prescribing triptans
Trytosaveabitスレ主Jaguar8:
It would be a really great thing! I had years of all kinds of meds for my migraines, including Demerol shots! Nothing worked until one of my Cardiologists recommended I try Wigraine/Ergotamine! And for a non-narcotic! It works where nothing else would even hardly touch the pain!
Trytosaveabitスレ主Jaguar8:
Yes, I know how terrible they can be! And yes certain people can’t take it! But for those who can, it’s a more than wonderful drug!
$イオン バイオファーマ インク A(AEON.US)$Aug 20, 2023 Daewoong Pharmaceutical Nabota/Pexuclu/Enblo Expansion of exports Daewoong Pharmaceutical Nabota/Pexuclu/Enblo Expansion of exports (postsen.com) "In addition, with the recent listing of AEON Biopharma, Inc., Nabota’s partner for treatment indications in developed countries, it plans to advance beyond the beauty market and into the treatment market to strengthen its competitiveness in the global market."
イオン バイオファーマ インク Aに関するコメント
this is depressing. wonder will the counter just get itself delisted from the market? people just treat the compat withour any single hope?
NEWS
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
AEON Biopharma announced that the preliminary results from the Phase 2 trial with ABP-450 for chronic migraine prevention did not meet the primary endpoint of mean reduction in monthly migraine days. The trial showed no statistical significance in reduction compared to placebo, leading to the company initiating cash preserva...
Dow Jones· 5 mins ago
1 MINUTE AGO, 4:30 PM EDT
VIA GLOBENEWSWIRE
– FDA and AEON align on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine –
– An interim analysis from the ongoing Phase 2 study in chronic migraine will now be conducted and data are e...
https://www.koreabiomed.com/news/articleView.html?idxno=22014
may i know what's happening? no trade??
Daewoong Pharmaceutical Nabota/Pexuclu/Enblo Expansion of exports (postsen.com)
"In addition, with the recent listing of AEON Biopharma, Inc., Nabota’s partner for treatment indications in developed countries, it plans to advance beyond the beauty market and into the treatment market to strengthen its competitiveness in the global market."
まだコメントはありません